Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out how often two investigational drugs that are given
together will shrink the patient's tumor and how well they will prolong the time it takes
their tumor to grow. The investigators also wish to find out how they affect certain
substances in the patient's tumor and in their blood important for tumor growth. The
combination of these drugs is experimental, and has not been proven to help treat melanoma